BIOGEN INC. (BIIB)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 2,645,500 | 2,431,000 | 2,465,800 | 2,464,900 |
| Selling, general and administrative | 583,800 | 572,500 | 588,400 | 553,800 |
| Restructuring charges | -700 | 35,300 | 6,800 | 6,600 |
| Research and development | 399,000 | 434,100 | 542,700 | 513,900 |
| Other (income) expense, net | -48,700 | -68,400 | -14,800 | -85,200 |
| Gain on sale of priority review voucher, net | - | - | - | 88,600 |
| Cost of sales, excluding amortization and impairment of acquired intangible assets | 605,000 | 629,300 | 638,700 | 546,000 |
| Business combination, contingent consideration, change in contingent consideration, liability, increase (decrease) | 13,200 | 9,600 | 23,800 | - |
| Acquired in-process research and development, upfront and milestone expense | 46,600 | 200,700 | - | - |
| Collaboration profit sharing/(loss reimbursement) | 75,000 | 58,100 | 69,300 | 62,400 |
| Amortization and impairment of acquired intangible assets | 130,900 | 111,800 | 130,300 | 86,900 |
| Total cost and expense | 1,901,500 | 2,119,800 | 2,014,800 | 1,766,200 |
| Income before income tax (benefit) expense | 744,000 | 311,200 | 451,000 | 698,700 |
| Income tax (benefit) expense | 109,200 | 70,700 | 62,500 | 115,100 |
| Netincome (loss) attributable to noncontrolling interests, netoftax | - | - | - | - |
| Net income (loss) | - | - | 388,500 | 583,600 |
| Net income attributable to biogen inc | 634,800 | 240,500 | 388,500 | 583,600 |
| Basic earnings per share attributable to biogen inc. (in usd per share) | 4.33 | 1.65 | 2.67 | 4.01 |
| Basic earnings per share attributable to biogen inc. (in usd per share) | 146,500,000 | 146,100,000 | 145,700,000 | 145,600,000 |
| Diluted earnings per share attributable to biogen inc. (in usd per share) | 4.33 | 1.64 | 2.66 | 4 |
| Diluted earnings per share attributable to biogen inc. (in usd per share) | 146,700,000 | 146,600,000 | 146,100,000 | 145,900,000 |